Intergroupe Francophone de Cancerologie Thoracique
Quick facts
Marketed products
- Customized Treatment · Oncology
Customized Treatment refers to personalized therapeutic approaches tailored to individual patient tumor characteristics and molecular profiles in thoracic oncology.
Phase 3 pipeline
- Chemotherapy with platine · Oncology
Platinum-based chemotherapy agents form DNA crosslinks that prevent cancer cell replication and induce apoptosis. - Gemcitabine alone · Oncology
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death. - Paclitaxel + Carboplatine · Oncology
Paclitaxel and carboplatin work synergistically to kill cancer cells by stabilizing microtubules and causing DNA damage, respectively.
Phase 2 pipeline
- Paclitaxel, vinorelbine, cisplatin
- Pembrolizumab after randomization · Oncology
PD-1 inhibitor - Pembrolizumab before randomization
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Intergroupe Francophone de Cancerologie Thoracique portfolio CI brief
- Intergroupe Francophone de Cancerologie Thoracique pipeline updates RSS
Frequently asked questions about Intergroupe Francophone de Cancerologie Thoracique
What are Intergroupe Francophone de Cancerologie Thoracique's marketed drugs?
Top marketed products include Customized Treatment.
What is Intergroupe Francophone de Cancerologie Thoracique's pipeline?
Intergroupe Francophone de Cancerologie Thoracique has 3 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include Chemotherapy with platine, Gemcitabine alone, Paclitaxel + Carboplatine.
Related
- Customized Treatment · Oncology
- Sector hub: All tracked pharma companies